<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598283</url>
  </required_header>
  <id_info>
    <org_study_id>18-0053</org_study_id>
    <nct_id>NCT03598283</nct_id>
  </id_info>
  <brief_title>Liver, Pancreas and Thyroid Function in Burn Patients</brief_title>
  <official_title>A Prospective Study to Evaluate the Outcome of Liver, Pancreas and Thyroid Function in Severely Burned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the extent to which severe burn injuries affect the
      morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be
      performed non-invasively with liver fibrosis scores based on standard blood parameters and
      the measurement of liver stiffness (correlated with liver fibrosis) and controlled
      attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography
      (FibroScan©, Echosens SA, Paris, France). The thyroid and the pancreas will be assessed via
      ultrasound (GE Medical Systems, Waukesha, USA) and standard blood parameters, respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective study, the extent to which severe burn injuries affect the morphology and
      function of liver, pancreas and thyroid. The evaluation of the liver will be performed
      non-invasively with liver fibrosis scores based on standard blood parameters, the
      ultrasound-guided measurement of the liver size and the measurement of liver stiffness
      (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with
      hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The
      thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by
      standard blood parameters only, respectively.

      The patient will be enrolled during the first days on their admission to the intensive care
      burn unit, if they meet the inclusion criteria and no exclusion criteria are met. The first
      assessment of liver, pancreas and thyroid function will be performed within the first 48
      hours of admission. The same measurements maybe be repeated approximately weekly until
      discharge, respectively. Furthermore at any follow-up visit up to 15 years post-burn if the
      patient consents to further participate in the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Liver stiffness (kPa)</measure>
    <time_frame>24 months</time_frame>
    <description>Measured via transient elastography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Controlled Attenuation Parameter</measure>
    <time_frame>24 months</time_frame>
    <description>Measured via transient elastography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver diameter (cm)</measure>
    <time_frame>24 months</time_frame>
    <description>Measured via Ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet count (/nl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-density lipoprotein (mg/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein (mg/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides (mg/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cholesterol (mg/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine-aminotransferase (U/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate-aminotransferase (U/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gamma glutamyltransferase (U/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline phosphatase (U/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin (ng/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin (g/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Liver function (blood tests)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thyroid volume (ml)</measure>
    <time_frame>24 months</time_frame>
    <description>Measured via Ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T3 level (ng/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Thyroid function (blood tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T4 level (ng/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Thyroid function (blood tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid-stimulating hormone level (U/l)</measure>
    <time_frame>24 months</time_frame>
    <description>Thyroid function (blood tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipase (U/l)</measure>
    <time_frame>24 months</time_frame>
    <description>Pancreas function (blood tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amylase (U/l)</measure>
    <time_frame>24 months</time_frame>
    <description>Pancreas function (blood tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height (kg)</measure>
    <time_frame>24 months</time_frame>
    <description>General patient data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>24 months</time_frame>
    <description>General patient data</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Burns</condition>
  <condition>Liver Fibroses</condition>
  <condition>Pancreas Disease</condition>
  <condition>Thyroid Diseases</condition>
  <arm_group>
    <arm_group_label>Severely burned patients</arm_group_label>
    <description>In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound/transient elastography</intervention_name>
    <description>The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.</description>
    <arm_group_label>Severely burned patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The investigator's study population will include pediatric as well as adult patients with
        any type of burn injury or toxic epidermal necrolysis (TENS).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with partial thickness burns. Only patients who sign an IRB-approved consent (≥18
        years old) or assent and have their legal guardian consenting to their participation (6
        months - 17 years old) will be included.

          -  Patient age &gt; 6 months

          -  Total body surface area (TBSA) burned ≥ 30 %

          -  Flame, electrical, scald or chemical injury, contact burn

          -  Toxic epidermal necrolysis (TENS)

        Exclusion Criteria:

          -  Patient &lt; 6 months

          -  TBSA burned &lt; 30 %
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients older than six months</gender_description>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Tapking, MD</last_name>
    <phone>409 770 6964</phone>
    <email>chtapkin@utmb.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Tapking, MD</last_name>
      <phone>409-770-6964</phone>
      <email>chtapkin@utmb.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

